The Gulf States Hemophilia & Thrombophilia Center
Welcome,         Profile    Billing    Logout  
 7 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Escobar, Miguel
ATHN 16, NCT04647227: SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Recruiting
4
55
US
coagulation factor VIIa [recombinant]-jncw, SEVENFACT
American Thrombosis and Hemostasis Network, LFB USA, Inc.
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
09/26
03/27
KEYSTONE 1, NCT06297486: Study of a Gene Therapy Treatment for Hemophilia A

Withdrawn
3
85
US
SPK-8011, AAV-Spark200-BDD-hFVIII, Dirloctocogene samoparvovec
Spark Therapeutics, Inc.
Hemophilia A
05/27
09/35
NCT05695391: A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

Recruiting
3
19
US, RoW
Coagulation Factor VIIa (Recombinant)
Laboratoire français de Fractionnement et de Biotechnologies
Hemophilia
06/25
07/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Active, not recruiting
2
60
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
02/25
NCT04055051: ATHN 11: Liver Transplantation Outcomes Study

Completed
N/A
86
US
American Thrombosis and Hemostasis Network, BioMarin Pharmaceutical
Hemophilia A and B, Liver Transplantation
12/22
12/22
NCT05904210: Retrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT®

Completed
N/A
17
US
SEVENFACT®
Laboratoire français de Fractionnement et de Biotechnologies
Hemophilia
05/24
05/24
NCT05568459: A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

Recruiting
N/A
120
Europe, Canada, US
Non-Interventional
Regeneron Pharmaceuticals
Hemophilia B
04/26
04/26
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35

Download Options